The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy
Open accessAbstract
The SET oncoprotein participates in cancer progression by affecting multiple cellular processes, inhibiting the tumor suppressor protein phosphatase 2A (PP2A), and inhibiting the metastasis suppressor nm23-H1. On the basis of these multiple activities, we hypothesized that targeted inhibition of SET would have multiple discrete and measurable effects on cancer cells. Here, the effects of inhibiting SET oncoprotein function on intracellular signaling and proliferation of human cancer cell lines was investigated. We observed the effects of COG112, a novel SET interacting peptide, on PP2A activity, Akt signaling, nm23-H1 activity and cellular migration/invasion in human U87 glioblastoma and MDA-MB-231 breast adenocarcinoma cancer cell lines. We found that COG112 interacted with SET protein and inhibited the association between SET and PP2A catalytic subunit (PP2A-c) and nm23-H1. The interaction between COG112 and SET caused PP2A phosphatase and nm23-H1 exonuclease activities to increase. COG112-mediated increases in PP2A activity resulted in the inhibition of Akt signaling and cellular proliferation. Additionally, COG112 inhibited SET association with Ras-related C(3) botulinum toxin substrate 1 (Rac1), leading to decreased cellular migration and invasion. COG112 treatment releases the SET-mediated inhibition of the tumor suppressor PP2A, as well as the metastasis suppressor nm23-H1. These results establish SET as a novel molecular target and that the inhibition of SET may have beneficial effects in cancer chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“SET is a physiologic PP2A inhibitor that binds directly to the PP2A/C subunit (Switzer et al., 2011). Consistent with the prevalent view that a fraction of PP2A holoenzymes exhibit tumor suppressor functions, SET appears to act as an oncogene.”
From PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer (2019) · cites this paper as Switzer et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhang, S., Han, J., Sells, M. A., Chernoff, J., Knaus, U. G., Ulevitch, R. J., & Bokoch, G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.23934 · Cited by 726
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677
Fan, Z., Beresford, P. J., Oh, D. Y., Zhang, D., & Lieberman, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00150-8 · Cited by 541
Protein phosphatase 2A regulatory subunits and cancer
Eichhorn, P. J. A., Creyghton, M. P., & Bernards, R. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2008.05.005 · Cited by 513
Seo, S.-B., McNamara, P., Heo, S., Turner, A., Lane, W. S., & Chakravarti, D. (2001) · Cell · doi:10.1016/s0092-8674(01)00196-9 · Cited by 481
Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development
Rosengard, A. M., Krutzsch, H. C., Shearn, A., Biggs, J. R., Barker, E. A., Margulies, I., King, C. R., Liotta, L. A., & Steeg, P. S. (1989) · Nature · doi:10.1038/342177a0 · Cited by 481
The Myeloid Leukemia-associated Protein SET Is a Potent Inhibitor of Protein Phosphatase 2A
Li, M., Makkinje, A., & Damuni, Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.19.11059 · Cited by 479
Lindern, M. V., van Baal, S., Wiegant, J. C. A. G., Raap, A. K., Hagemeijer, A., & Grosveld, G. C. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.8.3346 · Cited by 392
ErbB Receptor-induced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases
Olayioye, M. A., Beuvink, I., Horsch, K., Daly, J. M., & Hynes, N. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17209 · Cited by 373
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344
Cited by
Sorted by citations
Protein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400
All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312
Protein Ser/ Thr phosphatases – the ugly ducklings of cell signalling
Brautigan, D. L. (2012) · FEBS Journal · doi:10.1111/j.1742-4658.2012.08609.x · Cited by 231
Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer
Janghorban, M., Farrell, A. S., Allen-Petersen, B. L., Pelz, C., Daniel, C. J., Oddo, J., Langer, E. M., Christensen, D. J., & Sears, R. C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317630111 · Cited by 186
Self-citationReduced Insulin Production Relieves Endoplasmic Reticulum Stress and Induces β Cell Proliferation
Szabat, M., Page, M. M., Panzhinskiy, E., Skovsø, S., Mojibian, M., Fernandez-Tajes, J. J., Bruin, J. E., Bround, M. J., Lee, J. T. C., Xu, E. E., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.10.016 · Cited by 190
Metadata
- Authors
- Switzer, C. H., Cheng, R. Y. S., Vitek, T. M., Christensen, D. J., Wink, D. A., & Vitek, M. P.
- Affiliations
- National Institutes of Health (US)
- Cognosci (United States) (US)
- Duke Medical Center (US)
- Corresponding author
- Wink, D A
- Vitek, M P
- Venue
- Oncogene
- Published
- 2011-02-07
- Volume
- 30
- Issue
- 22
- Pages
- 2504-2513
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- PMC
- PMC3107340
- OpenAlex
- W2021359328
- Cited by
- 171
- References
- 50
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 3 · 2023: 11 · 2022: 12 · 2021: 12 · 2020: 9 · 2019: 10 · 2018: 11 · 2017: 16 · 2016: 15 · 2015: 14 · 2014: 15 · 2013: 14 · 2012: 15
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health
- National Cancer Institute (ZIASC007281, ZIABC010899)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- protein phosphatase 2A, nm23-H1, Akt signaling, cell proliferation, cell migration and invasion, Rac1, glioblastoma, breast adenocarcinoma, metastasis suppressor, tumor suppressor gene reactivation, cancer therapy targets
- MeSH terms
- Antineoplastic Agents, Cell Movement, DNA-Binding Proteins, Humans, Neoplasms, Peptides, Transcription Factors, Signal Transduction, rac1 GTP-Binding Protein, Cell Line, Tumor, Cell Proliferation, Proto-Oncogene Proteins c-akt, NM23 Nucleoside Diphosphate Kinases, Histone Chaperones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
